Drugs / MRx0005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05832775 | May 2022 → Apr 2023 | Parkinson disease | 4D pharma plc | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRx0005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05832775 ↗ |
| Known as | Parabacteroides distasonis | “Parabacteroides distasonis MRx0005 (Treatment B) and Placebo” NCT05832775 ↗ |
| Route | Oral | “repeat oral administrations of MRx0029 (20 participants) or MRx0005 (20 participants)” NCT05832775 ↗ |